Abstract
Recently, the Food and Drug Administration (FDA) issued an advisory that sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a risk of severe urinary tract infection (UTI) (1). They reported 19 patients with life-threatening sepsis due to UTI and severe pyelonephritis after initiating SGLT-2 inhibitors who required hospitalization. Some of them required admission to an intensive care unit or dialysis in order to treat acute renal failure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
